Day: February 4, 2024

BRISBANE, Australia, Feb. 05, 2024 (GLOBE NEWSWIRE) — NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or “the Company”), a leading battery materials and technology company, today announced the appointment of Sharan Burrow AC to its Board of Directors, effective 28 February, 2024. Chairman Robert J. Natter said: “Ms. Burrow is a global leader in creating thriving and diverse workplaces with responsible governance. She is also a sought-after leader in climate action and human rights and will prove invaluable to NOVONIX in our mission to advance clean energy. Ms. Burrow’s involvement in global policy dialogues with United Nations bodies, G7, G20, World Bank, and the International Monetary Fund brings unique expertise to the Board. I am delighted to welcome Ms. Burrow to the NOVONIX Board of Directors, recognizing her...

Figure 1.ELF Score — Change from Baseline at Week 12Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320 mg reduced liver fibrosis markers ELF and PRO-C3 and showed improvements in hepatocyte function and bile flow by contrast MRI imaging relative to placebo at Week 12 The 320 mg data continue to demonstrate antifibrotic effects of bexotegrast, consistent with previous findings Company to host webcast and conference call tomorrow, Monday, February 5 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced 12-week interim data from the 320 mg dose group of INTEGRIS-PSC, a multinational,...

SHENZHEN, CHINA, Feb. 03, 2024 (GLOBE NEWSWIRE) — China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 2 February 2024, the Group through its wholly-owned subsidiary entered into a Novation Agreement (the “Novation Agreement”) with Vifor Fresenius Medical Care Renal Pharma Ltd. (“VFMCRP”) and Winhealth Investment (HK) Limited (“Winhealth Investment”) for sucroferric oxyhydroxide chewable tablets Velphoro® (the “Product”). Winhealth Investment and VFMCRP entered into a License Agreement (the “License Agreement”) for the Product on 28 June 2023. In accordance with the License Agreement, Winhealth Investment gained an exclusive license to register，import, promote, distribute, use and sell the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region...